D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
NRIX holding history
Nurix Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NRIX overviewAll 13F holders of NRIXFull Q2 2026 holdings
- Shares (Q2 2026)
- 184,551
- Value
- $4.48M
- % of portfolio
- <0.1%
- Quarters held
- 12
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 184,551 | $4.48M | <0.1% | −159,652−46.4% | Reduced | Holders |
| Q1 2026 | 344,203 | $5.34M | <0.1% | +344,203 | New | Holders |
| Q2 2025 | 0 | $0 | 0.0% | −59,923−100.0% | Sold out | Holders |
| Q1 2025 | 59,923 | $711.9K | <0.1% | −52,918−46.9% | Reduced | Holders |
| Q4 2024 | 112,841 | $2.13M | <0.1% | +40,001+54.9% | Added | Holders |
| Q3 2024 | 72,840 | $1.64M | <0.1% | +72,840 | New | Holders |
| Q4 2023 | 0 | $0 | 0.0% | −25,358−100.0% | Sold out | Holders |
| Q3 2023 | 25,358 | $199.3K | <0.1% | −26,144−50.8% | Reduced | Holders |
| Q2 2023 | 51,502 | $514.5K | <0.1% | −7,535−12.8% | Reduced | Holders |
| Q1 2023 | 59,037 | $524.2K | <0.1% | −32,672−35.6% | Reduced | Holders |
| Q4 2022 | 91,709 | $1.01M | <0.1% | +31,695+52.8% | Added | Holders |
| Q3 2022 | 60,014 | $782.0K | <0.1% | +60,014 | New | Holders |
| Q3 2021 | 0 | $0 | 0.0% | −24,012−100.0% | Sold out | Holders |
| Q2 2021 | 24,012 | $637.0K | <0.1% | −17,186−41.7% | Reduced | Holders |
| Q1 2021 | 41,198 | $1.28M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.